Gestational Trophoblastic Disease

Key Mechanism 1: Abnormal Fertilization Events and Genomic Imbalancing

• Complete hydatidiform moles (CHM) arise from diploidization of a haploid sperm genome without contribution from maternal DNA, typically following fertilization of an empty egg by one or two sperm (androgenetic diploidy). This results in 90% of cases being 46,XX (from two maternal X-chromosomes from the sperm) and 10% being 46,XY. The complete absence of maternal genomic contribution leads to loss of maternal imprinting patterns critical for normal placental development, resulting in trophoblastic hyperplasia and minimal or absent embryonic tissue.
• Partial hydatidiform moles (PHM) arise from fertilization of a normal haploid egg by two sperm (diandric triploidy), resulting in an embryo with two sets of paternal genes and one set of maternal genes. This paternally imbalanced genome permits embryonic development (fetal tissue is present) but causes abnormal trophoblastic proliferation and the characteristic "partial" molar pattern with some normal chorionic villi interspersed with hydropic villi.
• The genomic imbalancing activates paternally-expressed growth-promoting genes (e.g., growth hormone, insulin-like growth factor II) while silencing maternal growth-restricting genes, creating a molecular environment favoring aggressive trophoblastic proliferation.

Key Mechanism 2: Trophoblastic Proliferation, Loss of Differentiation, and Reduced Apoptosis

• Normal trophoblastic development involves carefully regulated proliferation followed by differentiation into cytotrophoblast and syncytiotrophoblast with organized villous architecture. In GTD, trophoblastic cells undergo hyperplasia and dysplasia with retention of cytotrophoblastic features, loss of normal villous formation, and stromal edema (hydropic change).
• Abnormal paternally-imprinted gene expression silences tumor suppressor genes (such as those regulated by maternal p57) while activating proto-oncogenes, creating a milieu of reduced apoptosis and unchecked proliferation. This is particularly pronounced in complete moles, where complete absence of maternal gene contribution results in more aggressive trophoblastic proliferation compared to partial moles.
• The proliferating trophoblastic tissue produces massive amounts of β-hCG (far exceeding levels in normal pregnancy of equivalent gestational age), which drives continued endometrial proliferation and explains the characteristic vaginal bleeding and large-for-dates uteri seen clinically.

Key Mechanism 3: Abnormal Placentation, Vascular Invasion, and Metastatic Potential

• In addition to hyperproliferative trophoblast, GTD is characterized by abnormal placentation with increased villous invasion into the myometrium and intrinsic vascular abnormalities. The trophoblastic cells demonstrate loss of normal invasion barriers and acquire enhanced capacity for both local invasion and hematogenous spread.
• Histologically, non-neoplastic GTD (hydatidiform moles) shows hyperplastic trophoblastic tissue with hydropic villi and potential for local myometrial invasion (invasive mole). Neoplastic GTD (gestational trophoblastic neoplasia) demonstrates frank malignant transformation with cytologic atypia, abnormal mitotic figures, and documented metastatic spread.
• The pathophysiology of gestational trophoblastic neoplasia (GTN)—which develops in 15-20% of complete moles and 1-5% of partial moles after evacuation—involves acquisition of additional genetic alterations beyond the initial imprinting abnormality. These may include TP53 mutations, PTEN loss, and other oncogenic changes that drive transformation from benign molar tissue to invasive choriocarcinoma capable of hematogenous dissemination.

Key Mechanism 4: Excessive β-hCG Production and Endocrine Effects

• All forms of GTD produce β-hCG in excess of what would be expected for gestational age, because trophoblastic cells (especially syncytiotrophoblast) are the primary source of this hormone, and the abnormal proliferation in GTD dramatically increases the number of hormone-producing cells.
• The massively elevated β-hCG drives excessive endometrial proliferation, explaining the characteristic vaginal bleeding, and may trigger theca lutein cysts through stimulation of ovarian steroidogenesis. This can occasionally result in ovarian hyperstimulation and clinical consequences including pelvic pain and rarely ovarian torsion.
• In rare cases, extremely high β-hCG levels (>100,000 mIU/mL) can cause thyroid stimulation through cross-reactivity between β-hCG and TSH receptor, leading to clinical hyperthyroidism (gestational transient thyroidism).

Major Etiologic Categories: Benign vs. Neoplastic GTD

Benign Gestational Trophoblastic Disease: Hydatidiform Moles

• Complete Hydatidiform Mole (CHM): Results from androgenetic diploidy (sperm-derived genome without maternal genetic contribution). Accounts for ~80% of all molar pregnancies. The fertilization event involves penetration of an empty, non-nucleated oocyte by either a single sperm that duplicates its haploid genome (46,XX in most cases) or fertilization by two separate sperm. The complete absence of maternal nuclear DNA is the defining feature and explains the very high β-hCG levels, absence of fetal tissue, and higher risk of malignant transformation (15-20% progress to GTN).

• Partial Hydatidiform Mole (PHM): Results from diandric triploidy where a normal haploid egg is fertilized by two separate sperm (or one sperm that fails to complete meiosis), resulting in 69 chromosomes with two paternal and one maternal set. Accounts for ~10-15% of molar pregnancies. The presence of maternal genetic material permits embryonic tissue development, but the parental genomic imbalance causes trophoblastic abnormalities. Lower β-hCG levels than complete moles, presence of fetal tissue on imaging, and lower malignant potential (1-5% progress to GTN) are characteristic features.

Risk Factors for Gestational Trophoblastic Disease

• Maternal Age Extremes: Women aged <20 years and especially those >40 years have significantly increased risk, with risk rising markedly after age 35. The mechanism is thought to involve increased oocyte chromosomal nondisjunction in both very young women (meiotic inexperience) and older women (oocyte degeneration), predisposing to abnormal fertilization events. This age effect is among the strongest risk factors.

• Prior Molar Pregnancy: Recurrence risk is 1-2% after one molar pregnancy, rising to 15-25% after two consecutive moles. This dramatically increased recurrence with repeated molar pregnancies suggests a possible maternal genetic predisposition (though still hypothetical). Women with one or more prior molar pregnancies should be counseled about increased risk in subsequent pregnancies and should undergo careful β-hCG monitoring after any future conception.

• Race and Ethnicity: Significantly higher incidence in Asian and Hispanic populations, with rates 4-10 times higher in Southeast Asia compared to North America and Europe. This marked ethnic variation suggests possible genetic predisposition factors, though exact mechanisms remain unclear.

• Maternal Nutritional Factors: Some studies have suggested associations with folate and vitamin A deficiency, though evidence is not conclusive. This may reflect the role of these nutrients in normal DNA synthesis and cellular differentiation.

• Molecular Predisposition (NLRP7 and KHDC3L Mutations): Recent genetic studies have identified that approximately half of women with recurrent complete moles carry biallelic mutations in NLRP7 (nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 7), a gene critical for normal oocyte development and maternal-fetal genomic imprinting. Additional mutations in KHDC3L have been identified in some cases. These mutations predispose to androgenetic conceptuses (more likely to form complete moles).

• No Clear Association with Contraceptive Use or Abortion: Earlier literature suggested possible links to prior abortion or oral contraceptive use; however, modern studies do not support these associations.

Cardinal Presentations of Benign Molar Pregnancy

• Vaginal Bleeding: The most common presenting symptom, occurring in 80-90% of patients, typically beginning in the first or early second trimester. The bleeding results from excessive endometrial proliferation driven by the markedly elevated β-hCG levels. Bleeding is often more profuse and earlier than in normal miscarriage, and patients may initially seek care for "threatened miscarriage." The character of the bleeding may include passage of "grape-like" tissue (vesicular molar tissue), which is pathognomonic but occurs in only 15-20% of cases.

• Uterine Size Larger Than Expected for Gestational Age (Large-for-Dates Uterus): Occurs in approximately 50% of complete moles and 10% of partial moles. This disproportion between clinical and reported gestational age should raise suspicion for molar pregnancy. The excessive uterine size results from both the bulk of the molar tissue itself and the exaggerated endometrial proliferation stimulated by β-hCG. In contrast, in normal pregnancy, a uterus that is significantly larger than expected for dates more commonly indicates multiple gestation, polyhydramnios, or incorrect dating.

• Pelvic Pain and Pressure: Occurs in approximately 5-10% of patients with benign molar pregnancy, often secondary to theca lutein cysts (which occur in up to 50% of cases, particularly those with complete moles and very high β-hCG levels). These bilateral ovarian cysts result from excessive hCG-stimulated luteinization and can occasionally rupture, causing acute pelvic pain. In rare cases, massive bilateral cysts can lead to ovarian torsion.

• Hyperemesis Gravidarum: Nausea and vomiting are significantly more severe and frequent in molar pregnancy compared to normal pregnancy, occurring in 10-20% of cases with severe symptoms. This is related to the markedly elevated β-hCG levels; in fact, the severity of hyperemesis may be a clinical clue to the diagnosis of molar pregnancy in a patient with otherwise unexplained severe nausea.

• Pre-eclampsia in First or Early Second Trimester: Approximately 10-15% of molar pregnancies present with features of pre-eclampsia (hypertension, proteinuria, edema) occurring before 24 weeks gestation. This is highly unusual and should alert the clinician to the possibility of molar pregnancy, as genuine pre-eclampsia before 20 weeks is extremely rare. The pre-eclamptic features are thought to result from abnormal placentation (excessive trophoblastic invasion) combined with the effects of excess β-hCG and abnormal angiogenic factors.

• Thyroid Dysfunction (Gestational Transient Thyroidism): In cases with extremely elevated β-hCG (typically >100,000 mIU/mL), β-hCG cross-reacts with the TSH receptor, leading to transient thyrotoxicosis manifesting as tachycardia, tremor, and anxiety. This is more common in complete moles with very high hCG levels. Importantly, thyroid antibodies are absent, and the condition resolves with treatment of the molar pregnancy.

Clinical Features Distinguishing Complete vs. Partial Moles

Physical Examination Findings

• Uterine size larger than expected: Measured by fundal height or palpation, uterus is disproportionately large relative to reported gestational age.
• Bilateral adnexal masses: Theca lutein cysts may be palpable as bilateral ovarian masses; these are nearly always benign and regress after molar evacuation.
• Vaginal bleeding with passage of vesicular tissue: The characteristic "bunch of grapes" appearance of molar tissue passed per vaginum is pathognomonic but rare.
• Signs of pre-eclampsia: Hypertension (>140/90), proteinuria, hyperreflexia, and edema occurring before 20-24 weeks gestation.
• Signs of hyperthyroidism: Tachycardia, fine tremor, and hyperreflexia may be present in cases with very high β-hCG.

Clinical Presentation of Persistent Gestational Trophoblastic Neoplasia (GTN)

• Persistently elevated or rising β-hCG after evacuation (the most sensitive marker for persistent disease)
• Vaginal bleeding or bloody discharge persisting after evacuation
• Metastatic symptoms: Hemoptysis or respiratory symptoms (lung metastases in 80% of GTN), neurological symptoms (brain metastases), abdominal pain (liver or GI metastases)
• Sepsis or hemodynamic instability from perforation or rupture of metastatic lesions

Laboratory Diagnosis: β-hCG Quantification

• Markedly Elevated Quantitative β-hCG: This is the primary diagnostic clue. The diagnosis of molar pregnancy should be suspected when:
• β-hCG level exceeds 100,000 mIU/mL at <12 weeks gestation (extremely unusual in normal singleton pregnancy)
• Quantitative β-hCG is disproportionately high for reported gestational age compared to a dating curve (normal singleton pregnancy typically achieves 100,000-200,000 mIU/mL at 10-12 weeks, then plateaus and declines)
• In complete moles, β-hCG levels often range from 100,000 to >1,000,000 mIU/mL
• In partial moles, levels are typically only mildly elevated or may fall within the normal range for gestational age

Immediate stabilisation (before evacuation)

• Hemodynamic resuscitation: large-bore IV access, type and cross, transfuse for symptomatic anemia from heavy bleeding; correct coagulopathy.
• Beta blockade for hCG-mediated thyrotoxicosis: a beta blocker (e.g., propranolol) before induction of anesthesia, because surgical stress in an untreated thyrotoxic patient can precipitate thyroid storm.
• Blood pressure control and seizure prophylaxis with magnesium sulfate if pre-eclampsia with severe features is present; the definitive cure is evacuation.
• Anti-D immune globulin for Rh(D)-negative patients, since trophoblast expresses RhD.

First-line definitive therapy

• Suction (vacuum) curettage with sharp curettage, the ACOG-endorsed treatment for both complete and partial moles, performed under ultrasound guidance with uterotonics (oxytocin) started after cervical dilation to limit hemorrhage.
• Hysterectomy is a reasonable primary alternative for patients over 40 or those who have completed childbearing; it lowers but does not eliminate the risk of neoplasia, so surveillance continues. Theca lutein cysts and ovaries are left in place — they regress as hCG falls.

• Low-risk GTN: single-agent antimetabolite or antitumor antibiotic — methotrexate (with leucovorin rescue) or dactinomycin; switch agents for resistance.
• High-risk GTN: multiagent chemotherapy, classically EMA-CO (etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine), with consolidation cycles after hCG normalises.
• Placental site and epithelioid trophoblastic tumors are relatively chemoresistant — hysterectomy is the treatment of choice.

Peri-evacuation emergencies

• Hemorrhage: the bulky, highly vascular molar tissue and an atonic overdistended uterus cause brisk blood loss; signalled by tachycardia and falling hematocrit intraoperatively — treat with uterotonics, transfusion, and rarely hysterectomy. Emergency.
• Uterine perforation: soft, enlarged uterus with invasive trophoblast; signalled by sudden loss of resistance, hemoperitoneum, or instability. Emergency.
• Thyroid storm: hCG cross-reacts with the TSH receptor; anesthesia in an unrecognised thyrotoxic patient triggers fever, tachyarrhythmia, and delirium. Emergency — prevented by pre-op beta blockade.
• Trophoblastic pulmonary embolisation / cardiorespiratory distress: deportation of trophoblast plus fluid shifts, classically within hours of evacuating a uterus of >16 weeks' size, presenting as hypoxia, dyspnea, and diffuse infiltrates. Emergency.

Disease-related

• Persistent GTN/choriocarcinoma: additional oncogenic hits in retained trophoblast; signalled by a plateauing or rising β-hCG after evacuation, or new bleeding.
• Metastatic hemorrhage: choriocarcinoma invades vessels — hemoptysis or cannonball lung lesions, intracerebral bleed, or hepatic rupture with hemoperitoneum. Any neurologic change or hemodynamic collapse in a GTN patient is an emergency.
• Theca lutein cyst rupture or ovarian torsion: hCG-driven ovarian enlargement; acute unilateral pain with adnexal mass on ultrasound. Cysts otherwise regress and should not be resected.
• Early-onset pre-eclampsia/eclampsia and hyperemesis with electrolyte derangement.
• Anemia and Rh alloimmunisation.

Treatment-related

• Methotrexate: antifolate toxicity → mucositis, myelosuppression, transaminitis, serositis/pleuritic pain; monitor CBC and LFTs, rescue with leucovorin.
• Dactinomycin: severe nausea, alopecia, and vesicant extravasation injury.
• EMA-CO: myelosuppression with neutropenic fever, and etoposide-associated secondary leukemia plus earlier menopause with prolonged therapy.
• Hysterectomy: loss of fertility; surveillance still required.
• Phantom hCG from heterophile antibodies can prompt unnecessary chemotherapy — confirm with urine hCG or serial dilutions.

• Ultrasound buzzwords: complete mole = "snowstorm" / "cluster of grapes" echogenic mass with cystic spaces and no fetus; partial mole = focal cystic placental change with fetal parts. First-trimester scans may show only a heterogeneous mass, so hCG context matters.
• The single best next step in a first-trimester bleeder with a large-for-dates uterus: quantitative β-hCG plus pelvic ultrasound. Once molar pregnancy is confirmed, the next step is suction curettage — not misoprostol, not expectant management.
• The association examiners love: pre-eclampsia before 20 weeks = molar pregnancy until proven otherwise. The second favourite is hCG-driven hyperthyroidism with absent thyroid autoantibodies.
• p57^KIP2 immunostain is the histologic tiebreaker: it is maternally expressed, so it is negative in complete moles (no maternal genome) and positive in partial moles. Complete = 46,XX androgenetic; partial = 69,XXX/XXY diandric triploid.
• GTN is diagnosed by the hCG curve, not by biopsy: an hCG plateau or rise after evacuation, per FIGO criteria, is sufficient to start chemotherapy. Choriocarcinoma shows sheets of cyto- and syncytiotrophoblast without chorionic villi.
• Choriocarcinoma can follow any pregnancy — term delivery, abortion, or ectopic — so a postpartum woman with hemoptysis, cannonball pulmonary lesions, or a new neurologic deficit needs an hCG.
• Risk stratification drives drug choice: low WHO score → single-agent methotrexate or dactinomycin; high score → multiagent EMA-CO. Placental site trophoblastic tumor is the chemoresistant one → hysterectomy.
• Common distractors: do not surgically remove theca lutein cysts (they regress); a normal-appearing hysterectomy does not end hCG surveillance; and contraception during surveillance is mandatory — a new pregnancy's hCG masks relapse.